This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The online marketplace PartnerSlate has made waves in the food and beverage contractmanufacturing industry, recently securing a $4 million investment to further its mission of connecting food brands and contractmanufacturers. This is where San Francisco-based PartnerSlate comes in.
Streamlined development, flexibility in manufacturing, and improved product quality at reduced costs, while gaining access to capabilities and capacity are some of the factors fuelling the pharmaceutical solid dosage contractmanufacturing market.
In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contractmanufacturing organisations (CMOs). In order to achieve these plans, CAMP 4’s CEO, Josh Mandel-Brehm stated the company will prioritise raising capital through partnerships and businessdevelopment.
Ahead of CPHI North America, we caught up with Lisa Stiles, director, businessdevelopment at Selkirk Pharma, an exhibitor at the event, to find out how the CMO is navigating regulatory changes, challenges and more.
With over 18 years of experience, Alexander Dragitsch is a commercial customer service contractmanufacturing (CSCM) manager at Baxter’s Halle/Westfalen facility in Germany. The Halle customer service team is a “one-stop-shop” for client requests when it comes to commercial drug product manufacturing,” explains Dragitsch.
The dose form manufacturing follows API manufacturing to produce the final dosage form (FDF such as tablets and injectables. Commercial dose companies in contract marketing help in strategically positioning the products in the market, enabling patients to reap maximum benefit from it and transforming its sales management strategies.
Before the industry is set to arrive in San Diego for Bio International 2024, we spoke with Dr. Harald Oberegger, global head businessdevelopment at Novartis ContractManufacturing.
Pharmaceutical drug research and development (R&D) activities are capital-intensive, which makes the outsourcing of clinical dose manufacturing and marketing popular.
Research by GlobalData (Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition) shows that containment facilities are in high demand as the use of cytotoxic drugs continues to grow. What is driving the surge in demand for APIs?
Spreads also vary by industry sector with clinical research organizations and contractmanufacturing having the lowest gaps at 8 percent with medical device companies at the highest at almost 22 percent with biopharma (pre-commercial) following at nearly 21 percent.
Following the completion of the spin-off of the Upjohn Business(6) in the fourth quarter of 2020, Pfizer operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products worldwide.
Prior to Celgene, she held leadership roles in marketing, sales and new businessdevelopment from 2002 to 2011 at Johnson & Johnson. Shah previously served as Chief Executive Officer and a member of the board of directors of BioMotiv, an accelerator company aligned with the Harrington Project for Discovery & Development, a U.S.
Business Highlights. Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Corporate and BusinessDevelopment Update. Research and development (R&D). $. government. Operating Expenses.
to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. Billion Doses Expected to be Delivered in 2021 Under Signed Contracts as of Mid-April 2021.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content